Pharmacogenetic Contribution of Leptin Gene Polymorphism in Cutaneous T-Cell Lymphoma

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	VAŠKŮ Vladimír VAŠKŮ Anna BIENERTOVÁ VAŠKŮ Julie
Year of publication	2009
Type	Article in Periodical
Magazine / Source	International Journal of Clinical and Experimental Pathology
MU Faculty or unit	Faculty of Medicine
Citation
Field	Genetics and molecular biology
Keywords	leptin; gene polymorphism; pharmacogenetics; cutaneous T-cell lymphoma
Description	Abstract: Leptin has recently attracted more attention due to its specific effects in the pathogenesis of malignancies. The aim of this study was to investigate the possible association between variants of -2548 G/A polymorphism in leptin (LEP) gene and cutaneous T-cell lymphomas (CTCL), with respect to the treatment responsiveness. A sample of 91 patients with CTCL was compared to 198 control individuals. The CTCL men with AG and/or GG genotype were more likely to receive the topical steroids treatment (odds ratio 7.88, 95% confidential interval 1.51-41.04) when compared to AA patients. Our data supports the possible involvement of LEP-2548G/A polymorphism in CTCL treatment responsiveness and thus might provide important information for individual therapy tailoring.